Cloning and Functional Characterization of a σ Receptor from Rat Brain
暂无分享,去创建一个
[1] V. Ganapathy,et al. Exon‐Intron Structure, Analysis of Promoter Region, and Chromosomal Localization of the Human Type 1 σ Receptor Gene , 1998, Journal of neurochemistry.
[2] X. C. Lu,et al. Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. , 1997, Life sciences.
[3] G. Pasternak,et al. Synthesis and characterization of [125I]3′-(−)-iodopentazocine, a selective σ1 receptor ligand , 1997 .
[4] H. Glossmann,et al. The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. , 1997, Trends in pharmacological sciences.
[5] M. Kaghad,et al. Emopamil-binding Protein, a Mammalian Protein That Binds a Series of Structurally Diverse Neuroprotective Agents, Exhibits Δ8-Δ7 Sterol Isomerase Activity in Yeast* , 1996, The Journal of Biological Chemistry.
[6] E. Kempner,et al. Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[7] G. Pasternak,et al. Sigma antagonists potentiate opioid analgesia in rats , 1995, Neuroscience Letters.
[8] V. Ganapathy,et al. Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. , 1995, Endocrinology.
[9] F. Tortella,et al. σ receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures , 1995, Brain Research.
[10] G. Pasternak,et al. Selective antagonism of opioid analgesia by a sigma system. , 1994, The Journal of pharmacology and experimental therapeutics.
[11] J. Witkin. Pharmacotherapy of cocaine abuse: Preclinical development , 1994, Neuroscience & Biobehavioral Reviews.
[12] W. Bowen,et al. Characterization of a (+)-azidophenazocine-sensitive sigma receptor on splenic lymphocytes. , 1993, Journal of immunology.
[13] E. Schmid,et al. Identification of a 27-kDa high affinity phenylalkylamine-binding polypeptide as the sigma 1 binding site by photoaffinity labeling and ligand-directed antibodies. , 1993, Molecular pharmacology.
[14] R. Quirion,et al. Evidence for in vivo interactions between neuropeptide Y-related peptides and sigma receptors in the mouse hippocampal formation , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[15] H. Glossmann,et al. Biochemical characterization of a 22-kDa high affinity antiischemic drug-binding polypeptide in the endoplasmic reticulum of guinea pig liver: potential common target for antiischemic drug action. , 1993, Molecular pharmacology.
[16] D. DeHaven-Hudkins,et al. Allosteric modulation of ligand binding to [3H](+)pentazocine-defined sigma recognition sites by phenytoin. , 1993, Life sciences.
[17] G. Debonnel,et al. Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor. , 1992, The Journal of pharmacology and experimental therapeutics.
[18] H. Ericson,et al. Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain. , 1992, European journal of pharmacology.
[19] W. Bowen,et al. A proposal for the classification of sigma binding sites. , 1992, Trends in pharmacological sciences.
[20] S. Snyder,et al. σ Receptors: From Molecule to Man , 1991 .
[21] T. Su,et al. Solubilization and characterization of haloperidol-sensitive (+)-[3H]SKF-10,047 binding sites (sigma sites) from rat liver membranes. , 1991, The Journal of pharmacology and experimental therapeutics.
[22] A. Mahboubi,et al. Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. , 1991, Molecular pharmacology.
[23] J. Musacchio,et al. SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorphan and sigma ligands to guinea pig brain. , 1991, Life sciences.
[24] W. Bowen,et al. Sigma receptors: biology and function. , 1990, Pharmacological reviews.
[25] P. Rivière,et al. Neuropeptide Y and JO 1784, a selective sigma ligand, alter intestinal ion transport through a common, haloperidol-sensitive site. , 1990, European journal of pharmacology.
[26] W. Bowen,et al. A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain , 1990, Brain Research.
[27] C. Nemeroff,et al. Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. , 1990, The Journal of pharmacology and experimental therapeutics.
[28] C. Montigny,et al. N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors , 1990 .
[29] J. Cadet,et al. Sigma receptor blockade by BMY 14802 affects enkephalinergic and tachykinin cells differentially in the striatum of the rat. , 1990, European journal of pharmacology.
[30] Y. Itzhak,et al. Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. , 1990, Life sciences.
[31] B. Martin,et al. Neuropeptide Y and Peptide YY Interact with Rat Brain Sigma and PCP Binding Sites , 1990, European journal of pharmacology.
[32] E. London,et al. Cerebral metabolic effects of σ ligands in the rat , 1989, Brain Research.
[33] J. Musacchio,et al. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. , 1989, Molecular pharmacology.
[34] J. Musacchio,et al. High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions. , 1988, The Journal of pharmacology and experimental therapeutics.
[35] M. Kavanaugh,et al. Identification of the binding subunit of the sigma-type opiate receptor by photoaffinity labeling with 1-(4-azido-2-methyl[6-3H]phenyl)-3-(2-methyl[4,6-3H]phenyl)guanidine. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[36] F. J. White,et al. Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. , 1988, The Journal of pharmacology and experimental therapeutics.
[37] G. Vogeli,et al. Amplification, storage, and replication of libraries. , 1987, Methods in enzymology.
[38] D. Eisenberg,et al. Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.
[39] J. Thompson,et al. The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.
[40] W. Bowen,et al. Sigma-i and Sigma-2 Receptors Are Expressed in a Wide Variety of Human and Rodent Tumor Cell Lines , 2022 .